Apollon
🇷🇺Russia
A Phase I Trial of APL 400-003 Vaccine: Safety and Immune Response Evaluations of Multiple Injections at Escalating Doses in Asymptomatic HIV-Infected Patients
Phase 1
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Apollon
- Target Recruit Count
- 16
- Registration Number
- NCT00002350
- Locations
- 🇺🇸
Univ of Pennsylvania Med Ctr, Philadelphia, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath